Biannual Long-Acting Injection Shows Promise in Managing Resistant Hypertension
A groundbreaking six-month injection of zilebesiran shows significant promise in controlling resistant high blood pressure, potentially transforming hypertension treatment.
Recent findings from a clinical trial conducted by researchers at Queen Mary University of London highlight the potential of a new treatment approach for individuals with high blood pressure that remains uncontrolled despite standard therapies. The study, published in the Journal of the American Medical Association (JAMA), demonstrates that administering an injection every six months can lead to significant and sustained reductions in blood pressure levels.
The global KARDIA-2 trial involved 663 participants with hypertension inadequate response to traditional medications. Participants received zilebesiran, an investigational drug based on RNA interference technology, alongside their existing treatment. The results indicated that adding zilebesiran significantly improved blood pressure control compared to standard medication alone.
Hypertension affects approximately one in three adults in the UK, raising the risk of heart attacks, strokes, and other cardiovascular events if not properly managed. The current study's lead investigator, Dr. Manish Saxena, emphasized the importance of this breakthrough: "The long duration of action with just one injection every six months could revolutionize hypertension management and improve outcomes for millions."
Zilebesiran works by blocking the production of angiotensinogen in the liver, a precursor in blood vessel constriction processes. This mechanism promotes blood vessel relaxation, leading to lower blood pressure. The treatment is administered via subcutaneous injection and is being explored further in Phase 2 studies and large-scale outcome trials to assess its efficacy in broader patient populations including those with established cardiovascular disease.
Looking ahead, researchers plan to evaluate whether zilebesiran can prevent cardiovascular events such as strokes and heart attacks, potentially offering a long-term solution for resistant hypertension management.
This promising development underscores the ongoing advances in targeted therapies for complex health conditions, aiming to improve patient adherence and health outcomes.
[source: https://medicalxpress.com/news/2025-05-month-lowers-blood-pressure-patients.html]
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Skin Barrier Dysfunction Linked to Pediatric Eosinophilic Esophagitis: New Findings
New research reveals that skin barrier lipid abnormalities may serve as a noninvasive biomarker for diagnosing eosinophilic esophagitis in children, paving the way for innovative screening methods.
The Potential Link Between Nightmares and Increased Mortality Risk
Frequent nightmares are linked to a higher risk of early death and faster biological aging, highlighting the importance of managing sleep disturbances for overall health.
New Insights into How Human Eggs Maintain Longevity Could Improve IVF Outcomes
New research reveals that human eggs minimize cellular waste activity during maturation, a strategy that may enhance their longevity and improve IVF success rates. Discover how this minimalist approach to cellular maintenance can influence fertility treatments.
Biologists Monitor Jamestown Canyon Virus Spread in Pennsylvania Mosquitoes
Pennsylvania mosquitoes have tested positive for Jamestown Canyon virus, a mosquito-borne illness that can cause serious neurological and respiratory symptoms. Researchers emphasize the role of climate change in spreading these viruses and highlight preventive measures to reduce risk.